375 related articles for article (PubMed ID: 33131688)
1. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies.
Xie W; Huang H; Xiao S; Fan Y; Deng X; Zhang Z
Autoimmun Rev; 2020 Dec; 19(12):102687. PubMed ID: 33131688
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
Tison A; Quéré G; Misery L; Funck-Brentano E; Danlos FX; Routier E; Robert C; Loriot Y; Lambotte O; Bonniaud B; Scalbert C; Maanaoui S; Lesimple T; Martinez S; Marcq M; Chouaid C; Dubos C; Brunet-Possenti F; Stavris C; Chiche L; Beneton N; Mansard S; Guisier F; Doubre H; Skowron F; Aubin F; Zehou O; Roge C; Lambert M; Pham-Ledard A; Beylot-Barry M; Veillon R; Kramkimel N; Giacchero D; De Quatrebarbes J; Michel C; Auliac JB; Gonzales G; Decroisette C; Le Garff G; Carpiuc I; Vallerand H; Nowak E; Cornec D; Kostine M;
Arthritis Rheumatol; 2019 Dec; 71(12):2100-2111. PubMed ID: 31379105
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
Front Oncol; 2022; 12():934093. PubMed ID: 35912183
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis.
Liu X; Li S; Ke L; Cui H
BMC Cancer; 2024 Apr; 24(1):490. PubMed ID: 38632528
[TBL] [Abstract][Full Text] [Related]
5. Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis.
Yamaguchi A; Saito Y; Okamoto K; Narumi K; Furugen A; Takekuma Y; Sugawara M; Kobayashi M
Support Care Cancer; 2021 Dec; 29(12):7747-7753. PubMed ID: 34164739
[TBL] [Abstract][Full Text] [Related]
6. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.
Abdel-Wahab N; Shah M; Lopez-Olivo MA; Suarez-Almazor ME
Ann Intern Med; 2018 Jan; 168(2):121-130. PubMed ID: 29297009
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
Front Immunol; 2021; 12():730320. PubMed ID: 34646270
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis.
Cai Q; Huo GW; Zhu FY; Yue P; Yuan DQ; Chen P
Hum Vaccin Immunother; 2022 Dec; 18(7):2145102. PubMed ID: 36471629
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Immune Checkpoint Inhibitors in Cancer Patients and Preexisting Autoimmune Disease: A Systematic Review and Meta-Analysis in Non-Small-Cell Lung Cancer.
Aung WY; Lee CS; Morales J; Rahman H; Seetharamu N
Clin Lung Cancer; 2023 Nov; 24(7):598-612. PubMed ID: 37328320
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
Hilder R; Tsai K; Quandt Z; Isaacs D; Drakaki A; Xing Y; In GK; Angell TE; Lechner MG
Front Endocrinol (Lausanne); 2023; 14():1242830. PubMed ID: 38027216
[TBL] [Abstract][Full Text] [Related]
12. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
13. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population.
Li L; Li G; Rao B; Dong AH; Liang W; Zhu JX; Qin MP; Huang WW; Lu JM; Li ZF; Wu YZ
Sci Rep; 2020 Sep; 10(1):15567. PubMed ID: 32968172
[TBL] [Abstract][Full Text] [Related]
14. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
[TBL] [Abstract][Full Text] [Related]
15. Safety of immune checkpoint inhibitors in patients with preexisting autoimmune disorders.
Kumar R; Chan A; Bandikatla S; Ranjan S; Ngo P
Curr Probl Cancer; 2022 Aug; 46(4):100864. PubMed ID: 35671576
[TBL] [Abstract][Full Text] [Related]
16. Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis.
Efuni E; Cytryn S; Boland P; Niewold TB; Pavlick A; Weber J; Sandigursky S
J Clin Rheumatol; 2021 Oct; 27(7):267-271. PubMed ID: 31977647
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.
Reid P; Sandigursky S; Song J; Lopez-Olivo MA; Safa H; Cytryn S; Efuni E; Buni M; Pavlick A; Krogsgaard M; Abu-Shawer O; Altan M; Weber JS; Rahma OE; Suarez-Almazor ME; Diab A; Abdel-Wahab N
Oncoimmunology; 2023; 12(1):2261264. PubMed ID: 38126033
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
Zhang M; Fan Y; Nie L; Wang G; Sun K; Cheng Y
Chest; 2022 Jun; 161(6):1675-1686. PubMed ID: 35026298
[TBL] [Abstract][Full Text] [Related]
19. Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology.
Hoa S; Laaouad L; Roberts J; Ennis D; Ye C; Al Jumaily K; Pope J; Nevskaya T; Saltman A; Himmel M; Rottapel R; Ly C; Colmegna I; Fifi-Mah A; Maltez N; Tisseverasinghe A; Hudson M; Jamal S
Cancer Immunol Immunother; 2021 Aug; 70(8):2197-2207. PubMed ID: 33471137
[TBL] [Abstract][Full Text] [Related]
20. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
